VCEL Vericel Corporation

Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Second Quarter Fiscal Year End 2006 Investor Conference Call When: Wednesday, February 8, 2006 @ 10:00 AM (EST) Where: http://www.vcall.com/IC/CEPage.asp?ID=100120 How: -- For live over the Internet access, simply log on to the web at the address above. -- For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. -- To download the podcast, simply log on to the web at the address above. Contact: Kris Maly, Investor Relations Department, (734) 930-5777 or mail@aastrom.com If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ for 60 days. Through February 18, 2006, the audio replay of the call is available by dialing toll-free (877) 660-6853. When prompted on the phone, the Account # is 286, and the Conference ID# is 189683. Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, are manufactured in the AastromReplicell(R) System, an industry-unique automated cell production system. Aastrom's TRC cell products are in clinical trials for the following therapeutic indications: severe bone fractures (U.S.: Phase I/II - multi-center; EU: Phase I/II - multi-center), ischemic vascular disease (EU: Phase I/II), jaw bone reconstruction (EU: proof of concept) and spine fusion (U.S.: Phase I/II - single-center). The Company has recently reported positive clinical trial results for its TRCs demonstrating both the clinical safety and ability of TRCs to induce healthy new tissue growth. For more information, visit Aastrom's website at www.aastrom.com.